SCHEMBL2898441

SCHEMBL2898441

O=C1c2c(O)c(=O)n(CCc3cccs3)c(=O)n2CCN1Cc1ccc(F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.48
HDAC1 Q13547 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
KCNH2 Q12809 1/20 0.39
GRM2 Q14416 1/20 0.39
NPC1 O15118 1/20 0.39
MAPT P10636 2/20 0.38
KMT2A Q03164 1/20 0.38
LMNA P02545 2/20 0.38
POLB P06746 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
HPGD P15428 2/20 0.36
AKR1B1 P15121 1/20 0.36
GAA P10253 1/20 0.36
ALDH1A1 P00352 2/20 0.35
PKM P14618 2/20 0.35
USP2 O75604 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2891898 0.77 KCNH2 (0.42) HDAC1HDAC11HDAC8HDAC6KCNH2
SCHEMBL2895253 0.77 KCNH2 (0.39) HDAC1HDAC11HDAC8HDAC6KCNH2
SCHEMBL2890924 0.77 KCNH2 (0.45) HDAC1HDAC11HDAC8HDAC6KCNH2
SCHEMBL2898603 0.76 DRD4 (0.41) TSHRKCNH2GRM2NPC1KMT2A
SCHEMBL13085964 0.75 RGS4 (0.40) HDAC1HDAC11HDAC8HDAC6KCNH2
SCHEMBL2892046 0.74 KCNH2 (0.40) TSHRKCNH2GRM2NPC1KMT2A
SCHEMBL2892150 0.74 CYP19A1 (0.45) TSHRKCNH2GRM2KMT2APOLB
SCHEMBL13094029 0.74 CYP2D6 (0.38) HDAC1HDAC11HDAC8HDAC6KCNH2
SCHEMBL2900405 0.73 FEN1 (0.40) KCNH2GRM2KMT2APOLBAKR1B1
SCHEMBL13085966 0.72 AKR1B1 (0.35) TSHRKCNH2GRM2LMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US claimed
EP-1725102-A4 HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2009-04-29 EP claimed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US claimed
EP-1725102-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005092099-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-10-06 WO claimed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009490-A1 Hiv Integrase Inhibitors TYMS, UNG, TYMP TSHR 4386/4885HDAC1 1081/4885HDAC11 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.